Liquid Semaglutide: What Patients Need to Know About This Controversial Formulation

Liquid Semaglutide: What Patients Need to Know About This Controversial Formulation

By Dr. Onikepe Adegbola, MD PhD

Liquid semaglutide has become the most talked-about formulation in the GLP-1 space, and for reasons that should concern anyone considering it. Unlike FDA-approved injectable pens (Ozempic, Wegovy) or oral tablets (Rybelsus), this compounded formulation is a product — manufactured by compounding pharmacies and sold primarily through telehealth subscription services. It's cheaper, more accessible, and carries risks that most marketing materials conveniently omit.

I prescribe semaglutide regularly in my practice at Mochi Health. I've seen the good outcomes. I've also treated patients who came to me after bad experiences with poorly compounded liquid formulations. Here's what you need to understand before choosing this route.

What Liquid Semaglutide Actually Is

Semaglutide exists in three legitimate forms. Novo Nordisk manufactures injectable semaglutide (Ozempic for diabetes, Wegovy for weight loss) and oral semaglutide (Rybelsus). These went through years of clinical trials, rigorous manufacturing controls, and FDA review.

The compounded version is different. Compounding pharmacies purchase semaglutide base powder and mix it into a liquid solution — typically for subcutaneous injection, sometimes as sublingual drops. This became possible at scale because semaglutide was listed on the FDA Drug Shortage List, which opened the door for compounders to legally produce it.

The appeal is obvious. Brand-name Wegovy costs over $1,300 per month without insurance. Compounded versions run $200-$500. For patients priced out of the brand-name market — which is most patients — the math is compelling.

But cheaper doesn't mean equivalent.

The Compounding Quality Problem

Not all compounding pharmacies operate at the same standard. The distinction that matters: 503A pharmacies compound on a patient-specific basis with lighter regulatory oversight. 503B outsourcing facilities operate under stricter FDA inspection and batch-testing requirements.

In my clinical experience, I've seen patients using product from 503B facilities do quite well. Consistent dosing. Predictable effects. Results comparable to brand-name formulations. But I've also seen patients using compounded product from less rigorous sources who experienced wildly inconsistent results — losing 8 pounds one month, nothing the next, then sudden severe nausea suggesting a potency spike.

The FDA's concerns are documented. Between 2023 and 2025, the agency issued warnings about compounded semaglutide products containing salt forms (semaglutide sodium, semaglutide acetate) that differ from the base form used in clinical trials. Whether these salt forms produce equivalent effects remains scientifically unclear. That uncertainty alone gives me pause.

How the Compounded Formulation Differs from FDA-Approved Versions

Patients often ask me: "Isn't it the same molecule?" Technically, the active ingredient is semaglutide in all cases. But formulation matters more than people realize.

FDA-approved injectable semaglutide uses a specific buffer solution, preservatives, and pH balance that Novo Nordisk refined over years of development. The delivery pen provides exact dosing — you dial up your dose and inject. Reproducibility is built into the device.

The compounded formulation comes in a vial. You draw it up with a syringe. The concentration, stability, and sterility depend entirely on the pharmacy that made it. Some are excellent. Some are not. You typically can't tell the difference by looking at the vial.

Sublingual Compounded Formulations

Some programs now offer the compounded formulation as sublingual drops — placed under the tongue rather than injected. This is the formulation that concerns me most. Oral semaglutide (Rybelsus) required a specific absorption enhancer called SNAC to achieve meaningful bioavailability, and even then, absorption sits around 0.4-1%. A sublingual liquid without this technology has unpredictable absorption at best.

I've seen patients on sublingual formulations who experienced virtually no appetite suppression. Others had inconsistent effects. The pharmacokinetics simply haven't been studied for this delivery method. You're paying for a formulation without evidence that it works as intended.

Safety Considerations with Compounded Semaglutide

The side effect profile of semaglutide is well-documented from clinical trials: nausea, vomiting, diarrhea, constipation, abdominal pain. These GI effects occur in 40-60% of patients and are dose-dependent. With proper titration — starting at 0.25mg weekly and increasing gradually — most patients tolerate the medication well.

The compounded formulation introduces an extra variable. If the concentration is slightly off, your "0.5mg dose" might actually be 0.4mg one week and 0.6mg the next. That inconsistency makes titration harder and side effects less predictable.

GI Side Effects and Nutritional Support

Regardless of which semaglutide formulation you use, the GI side effects are real and need management. In my practice, I see three patterns repeatedly:

• Early nausea and appetite suppression — Usually worst in weeks 1-4 of each dose increase. Manageable but unpleasant.
• Constipation that builds over time — GLP-1 medications slow gastric motility. This effect accumulates, especially at higher doses.
• Nutrient absorption changes — Patients eating less while their gut transit slows creates a perfect storm for vitamin and mineral deficiencies.

These issues exist with brand-name Wegovy too. But with liquid semaglutide, unpredictable dosing can make them worse. Patients may experience sudden nausea spikes that they weren't expecting — a sign that a particular batch may have been slightly more concentrated.

I recommend that all patients on semaglutide — compounded or brand-name — work with a provider who monitors nutritional status and supports gut health throughout treatment. Casa de Sante GLP-1 supplements were developed specifically for this purpose, formulated to be low-FODMAP and gut-gentle for patients whose digestive systems are already under stress from GLP-1 therapy.

How to Evaluate a Compounded Semaglutide Program

If you're considering the compounded formulation — and I understand the financial pressures that make it attractive — here's what to look for and what to avoid.

Green Flags

• The pharmacy is 503B-registered with FDA inspection history you can verify
• The program requires labs before starting (metabolic panel, A1c, thyroid function at minimum)
• A licensed physician reviews your history and manages your care — not just signs off on prescriptions
• Dose titration follows standard protocols (0.25mg → 0.5mg → 1mg → 1.7mg → 2.4mg)
• Regular follow-up visits are included, not sold as add-ons
• The program discusses diet, exercise, and nutritional support alongside the medication

Red Flags

• No labs required before or during treatment
• "One-size-fits-all" dosing without individualized titration
• No physician oversight — only a nurse practitioner rubber-stamping prescriptions in a state they've never visited
• Sublingual formulation presented as equivalent to injectable
• Claims of "pharmaceutical grade" without third-party testing documentation
• No mention of side effect management or nutritional monitoring

The quality of medical oversight matters as much as the quality of the compounding. A compounded formulation prescribed by a physician who monitors your progress, adjusts your dose appropriately, and addresses side effects proactively is a fundamentally different experience than a subscription box that ships vials to your door.

Supporting Your Body on Any Semaglutide Formulation

Whether you're on brand-name Wegovy, a compounded formulation, or oral Rybelsus, the physiological challenges are similar. You're eating significantly less. Your gut motility has slowed. Your body still needs the same vitamins, minerals, and protein — maybe more, not less, because you're in a caloric deficit.

In my practice, I've developed a structured support approach for GLP-1 patients:

Protein prioritization. Aim for 1.0-1.2 grams per kilogram of body weight daily. When appetite is suppressed, a GLP-1 Companion Whey Protein shake can provide 20-25 grams in a form your GI system can handle.

Digestive enzyme support. Slower gastric emptying means food sits longer. A GLP-1 Digestive Enzyme Companion helps break down meals more efficiently, reducing bloating and discomfort.

Micronutrient coverage. A GLP-1 Daily Nutrition Companion fills the gaps that reduced food intake creates. B12, iron, magnesium, and vitamin D are the most common deficiencies I see in my GLP-1 patients.

Frequently Asked Questions

Is liquid semaglutide FDA-approved?

No. No. It is a compounded product, not an FDA-approved formulation. FDA-approved semaglutide products include Ozempic and Wegovy (injectable) and Rybelsus (oral tablet). Compounded versions are legal during drug shortages but have not undergone the same clinical testing and manufacturing oversight.

Is liquid semaglutide as effective as Wegovy?

If compounded correctly to the appropriate concentration and administered via injection, the compounded formulation should produce similar effects because the active molecule is the same. However, "compounded correctly" is the operative phrase. Potency and consistency vary between pharmacies. Sublingual liquid formulations have not demonstrated equivalent efficacy.

Why is liquid semaglutide so much cheaper?

Compounding pharmacies don't bear the costs of clinical trials, FDA approval processes, or brand marketing. They purchase bulk semaglutide powder and produce it at a fraction of the cost. Lower prices are real, but so is the reduced regulatory oversight that comes with them.

What happens when the semaglutide shortage ends?

When the drug is no longer on the FDA shortage list, compounding pharmacies lose the legal basis to produce it. The FDA announced in late 2024 that the shortage was resolved for certain formulations, which prompted legal battles and regulatory uncertainty. Patients on compounded formulations should have a plan for transitioning to FDA-approved alternatives if their supply is interrupted.

Can I switch from liquid semaglutide to Wegovy or Ozempic?

Yes, though dose equivalence requires careful physician management. The transition should be supervised — don't assume your compounded dose maps directly to a specific pen setting. Your provider can determine the appropriate brand-name dose based on your current response and tolerance.